01:55 PM EST, 11/25/2025 (MT Newswires) -- Lixte Biotechnology ( LIXT ) said Tuesday it closed the acquisition of Liora Technologies Europe to leverage the UK-based company's proton therapy systems for treating tumors in various cancers.

The acquisition includes Liora's Linac for Image-Guided Hadron Therapy system, which provides a proton beam capable of delivering high dose rates to tumors, according to a statement.

The system is also expected to lower installation costs and treatment sessions while increasing the capacity of treatment centers to treat more patients. The company said the proton therapy system could enable it to create a recurring revenue model via jointly operated treatment centers.

Shares of Lixte fell 10.5% in recent trading.

Price: 4.00, Change: -0.47, Percent Change: -10.51